JP2016006108A5 - - Google Patents

Download PDF

Info

Publication number
JP2016006108A5
JP2016006108A5 JP2015162398A JP2015162398A JP2016006108A5 JP 2016006108 A5 JP2016006108 A5 JP 2016006108A5 JP 2015162398 A JP2015162398 A JP 2015162398A JP 2015162398 A JP2015162398 A JP 2015162398A JP 2016006108 A5 JP2016006108 A5 JP 2016006108A5
Authority
JP
Japan
Prior art keywords
dosage form
oral pharmaceutical
pharmaceutical dosage
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015162398A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016006108A (ja
Filing date
Publication date
Priority claimed from EP06119839A external-priority patent/EP1897543A1/en
Application filed filed Critical
Publication of JP2016006108A publication Critical patent/JP2016006108A/ja
Publication of JP2016006108A5 publication Critical patent/JP2016006108A5/ja
Pending legal-status Critical Current

Links

JP2015162398A 2006-08-30 2015-08-20 薬物置換療法のためのブプレノルフィンウェハー Pending JP2016006108A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06119839.6 2006-08-30
EP06119839A EP1897543A1 (en) 2006-08-30 2006-08-30 Buprenorphine- wafer for drug substitution therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2012273780A Division JP2013079265A (ja) 2006-08-30 2012-12-14 薬物置換療法のためのブプレノルフィンウェハー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017108044A Division JP2017206517A (ja) 2006-08-30 2017-05-31 薬物置換療法のためのブプレノルフィンウェハー

Publications (2)

Publication Number Publication Date
JP2016006108A JP2016006108A (ja) 2016-01-14
JP2016006108A5 true JP2016006108A5 (enExample) 2016-02-25

Family

ID=37685660

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009526094A Pending JP2010501628A (ja) 2006-08-30 2007-08-29 薬物置換療法のためのブプレノルフィンウェハー
JP2012273780A Pending JP2013079265A (ja) 2006-08-30 2012-12-14 薬物置換療法のためのブプレノルフィンウェハー
JP2015162398A Pending JP2016006108A (ja) 2006-08-30 2015-08-20 薬物置換療法のためのブプレノルフィンウェハー
JP2017108044A Pending JP2017206517A (ja) 2006-08-30 2017-05-31 薬物置換療法のためのブプレノルフィンウェハー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2009526094A Pending JP2010501628A (ja) 2006-08-30 2007-08-29 薬物置換療法のためのブプレノルフィンウェハー
JP2012273780A Pending JP2013079265A (ja) 2006-08-30 2012-12-14 薬物置換療法のためのブプレノルフィンウェハー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017108044A Pending JP2017206517A (ja) 2006-08-30 2017-05-31 薬物置換療法のためのブプレノルフィンウェハー

Country Status (18)

Country Link
US (8) US9101625B2 (enExample)
EP (2) EP1897543A1 (enExample)
JP (4) JP2010501628A (enExample)
AU (1) AU2007291245A1 (enExample)
CA (1) CA2661759C (enExample)
CY (1) CY1114139T1 (enExample)
DE (1) DE202006018608U1 (enExample)
DK (1) DK2059243T3 (enExample)
ES (1) ES2411179T3 (enExample)
HR (1) HRP20130344T1 (enExample)
IL (1) IL197316A (enExample)
ME (1) ME02081B (enExample)
MX (1) MX2009002196A (enExample)
PL (1) PL2059243T3 (enExample)
PT (1) PT2059243E (enExample)
RS (1) RS52831B (enExample)
SI (1) SI2059243T1 (enExample)
WO (1) WO2008025791A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090178885A1 (en) * 2008-01-14 2009-07-16 Heath William J Ladder and walkboard support
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
JP2011525536A (ja) * 2008-06-23 2011-09-22 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 多方向性粘膜送達装置および使用法
CN102686221B (zh) * 2009-07-27 2018-04-17 诺西赛普塔有限责任公司 治疗疼痛的方法
US8475832B2 (en) * 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN103209681B (zh) 2010-06-10 2017-05-24 Mida科技有限公司 纳米颗粒薄膜递送系统
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
EA029507B1 (ru) 2011-09-19 2018-04-30 Орексо Аб Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CN110123792A (zh) * 2011-12-21 2019-08-16 拜欧帝力威瑞科学有限公司 用于慢性疼痛缓解的跨粘膜药物传递装置
ES2802976T3 (es) 2013-09-10 2021-01-22 Fresh Cut Dev Llc Pulverizador de buprenorfina sublingual
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11389473B2 (en) 2015-01-07 2022-07-19 Tonix Pharmaceuticals Holding Corp. Magnesium-containing oxytocin formulations and methods of use
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
EP4631569A3 (en) 2016-11-15 2025-12-24 Klaria Pharma Holding AB Alginate film comprising a triptan
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US11439496B2 (en) 2017-10-20 2022-09-13 SB-Kawasumi Laboratories, Inc. Tubular therapeutic implement, tubular therapeutic implement set, and device for indwelling tubular therapeutic implement
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2020006073A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
AU2020259128A1 (en) * 2019-04-18 2021-12-09 Chiesi Farmaceutici S.P.A. Method for treating neonatal opiod withdrawal syndrome
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
WO2021158957A1 (en) 2020-02-05 2021-08-12 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
EP4151204A1 (de) * 2021-09-17 2023-03-22 LTS Lohmann Therapie-Systeme AG Schnell zerfallende orale dünne filme/schäume mit hoher wirkstoffbeladung auf basis eines gemisches von polyvinylalkoholen mit unterschiedlichen molekulargewichten
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
GB1390772A (en) 1971-05-07 1975-04-16 Endo Lab Oral narcotic composition
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
DE2746414A1 (de) 1977-10-15 1979-04-26 Gerlach Eduard Chem Fab Mittel zum dosieren von stoffen und verfahren zu seiner herstellung
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8514665D0 (en) 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4889860A (en) 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
WO1991004757A1 (en) 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5633259A (en) 1992-09-21 1997-05-27 United Biomedical, Inc. Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction
US20010006967A1 (en) 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
NZ302723A (en) * 1995-03-02 1998-04-27 Scherer Ltd R P Composition comprising monoamine oxidase b inhibitor and a carrier formulated for pre-gastric absorption of the monoamine oxidase b inhibitor
JP3731612B2 (ja) 1995-04-21 2006-01-05 東洋紡績株式会社 口腔粘膜貼付ブプレノルフィン製剤
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
GB2328443B (en) * 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
BR9806303A (pt) 1997-10-07 2000-03-14 Fuisz Technologies Ltd Sistema de distrituição de droga termoformado, e, unidade de dosagem
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
PT1041987E (pt) 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
TR200001828T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem.
AR018143A1 (es) 1998-03-06 2001-10-31 Eurand Internat Spa Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
AU5470099A (en) 1998-08-12 2000-03-06 Fuisz Technologies Ltd. Products containing unpleasant tasting bio-affecting agents and methods of making them
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
GB9904629D0 (en) 1999-03-02 1999-04-21 Danbiosyst Uk Oral drug delivery system
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6210699B1 (en) * 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
SI1299104T1 (sl) 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CA2416698A1 (en) 2000-07-17 2002-01-24 University Of Utah Hydrogel films and methods of making and using therefor
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2003003957A1 (en) 2001-07-06 2003-01-16 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20150031718A1 (en) 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
JP4504013B2 (ja) 2001-08-06 2010-07-14 ユーロ−セルティーク エス.エイ. 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
DK2332523T4 (da) 2001-10-12 2022-02-21 Aquestive Therapeutics Inc Ensartede film til hurtigtopløsende doseringsform indeholdende smagsmaskerende præparater
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
DE10207394B4 (de) 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20050245556A1 (en) 2002-04-05 2005-11-03 Bianca Brogmann Pharmaceutical preparation containing oxycodone and naloxone
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
WO2005004989A2 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0403808D0 (en) 2004-02-20 2004-03-24 Bioprogress Technology Ltd Films for use as dosage forms
DE102005007859A1 (de) 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
CA2629046C (en) * 2005-12-13 2014-04-08 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US20070185145A1 (en) 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
US20070196494A1 (en) 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
DE102006027793A1 (de) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Opioid-Kombinations-Wafer
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
DK2248519T3 (en) 2006-10-02 2018-01-02 Applied Pharma Res Non-mucoadhesive film dosage forms
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Similar Documents

Publication Publication Date Title
JP2016006108A5 (enExample)
US11207270B2 (en) Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
JP2016199602A5 (enExample)
CA2704646C (en) Sustained-release tablets with hydromorphone
JP2008503475A5 (enExample)
CN1525855A (zh) 治疗与预防心脏病与循环系统疾病的日服一次疗法用口服的控释医药组合物
JP2009545560A5 (enExample)
JP2017019858A5 (enExample)
CN113908153B (zh) 一种布瓦西坦药物组合物、其制备方法及应用
JP2018517676A5 (enExample)
JP2013545762A5 (enExample)
JP2019506401A5 (enExample)
IL303767A (en) Pharmaceutical formulations of centrapadin, and methods for its preparation and use
CN101628002B (zh) 一种微粉化的含左炔诺孕酮的组合物
CN114845700A (zh) Otf的可溶性背衬层
CN105025888B (zh) 肠溶片
CN102091053B (zh) 一种颗粒组合控释片
CA2529393A1 (en) Sustained release formulation for venlafaxine hydrochloride
CN117482069A (zh) 一种盐酸格拉司琼口溶膜剂及其制备方法
JP2018521139A5 (enExample)
EP1512394B1 (en) Universal controlled-release composition comprising chitosan
JP2010506855A5 (enExample)
WO2015085739A1 (zh) 一种多层固体药物剂型
WO2024220974A1 (en) Rimegepant fast-dissolving films for oral administration
TW202315862A (zh) 布瓦西坦藥物組合物、其製備方法及應用